The Effects of Real-World Evidence on the Treatment of HER2+ mBC - Episode 11
Treatment Sequencing Approaches for Patients With HER2+ mBC
Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.
Related Content:
